Metsera (MTSR) Hits New High on Billion-Dollar Bidding War

We recently published 10 Stocks on Fire Amid Market Chaos. Metsera, Inc. (NASDAQ:MTSR) is one of the best-performing stocks on Thursday.

Metsera soared to a new all-time high on Thursday as buying appetite was bolstered by an intensifying billion-dollar bidding war from two pharmaceutical giants.

At intra-day trading, Metsera, Inc. (NASDAQ:MTSR) climbed to a new high of $82.79 before trimming gains to end the day just up by 14.25 percent at $81.55 apiece.

Africa Studio/Shutterstock.com

This followed news that Pfizer Inc. upgraded its offer to buy Metsera, Inc. (NASDAQ:MTSR) for $10 billion, matching Novo Nordisk’s, albeit the latter said its offer remained higher.

The bidding war began privately in January this year, with both companies aiming to gain a foothold and a larger market share in the booming weight-loss market.

Earlier this year, Pfizer shelved a clinical trial for its own weight-loss drug candidate amid safety concerns and shifted its sights on acquiring Metsera, Inc. (NASDAQ:MTSR) to reenter the space. Meanwhile, Novo Nordisk moved to tighten its grip after losing ground to its largest rival, Eli Lilly.

Metsera, Inc. (NASDAQ:MTSR) already signed a definitive agreement to be acquired by Pfizer last month, but later walked back following Novo’s higher offer.

Pfizer later sued Metsera and Novo for breaching the definitive agreement, saying that the latter’s move “constitutes an anticompetitive action … to protect its dominant market position in GLP-1s.”

While we acknowledge the risk and potential of MTSR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MTSR and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.